Haese A - Search Results

1

Impact of surgical experience on in-hospital complication rates in patients undergoing minimally invasive prostatectomy: a population-based study.

Budäus L, Sun M, Abdollah F, Zorn KC, Morgan M, Johal R, Liberman D, Thuret R, Isbarn H, Salomon G, Haese A, Montorsi F, Shariat SF, Perrotte P, Graefen M, Karakiewicz PI. Budäus L, et al. Among authors: haese a. Ann Surg Oncol. 2011 Mar;18(3):839-47. doi: 10.1245/s10434-010-1300-0. Epub 2010 Oct 16. Ann Surg Oncol. 2011. PMID: 20953720

2

Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.

Haese A, Graefen M, Noldus J, Hammerer P, Huland E, Huland H. Haese A, et al. J Urol. 1997 Dec;158(6):2188-92. doi: 10.1016/s0022-5347(01)68192-8. J Urol. 1997. PMID: 9366341

3

Incidence of positive surgical margins after biopsy-selected nerve-sparing radical prostatectomy.

Graefen M, Hammerer P, Michl U, Noldus J, Haese A, Henke RP, Huland E, Huland H. Graefen M, et al. Among authors: haese a. Urology. 1998 Mar;51(3):437-42. doi: 10.1016/s0090-4295(97)00608-0. Urology. 1998. PMID: 9510349

4

Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.

Haese A, Huland E, Graefen M, Hammerer P, Noldus J, Huland H. Haese A, et al. J Urol. 1999 Apr;161(4):1206-11. J Urol. 1999. PMID: 10081870 Clinical Trial.

5

Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.

Graefen M, Noldus J, Pichlmeier U, Haese A, Hammerer P, Fernandez S, Conrad S, Henke R, Huland E, Huland H. Graefen M, et al. Among authors: haese a. Eur Urol. 1999;36(1):21-30. doi: 10.1159/000019922. Eur Urol. 1999. PMID: 10364651

6

Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure.

Haese A, Huland E, Graefen M, Huland H. Haese A, et al. Anticancer Res. 1999 Jul-Aug;19(4A):2641-4. Anticancer Res. 1999. PMID: 10470210

7

[Prognostic markers for prostate cancer].

Graefen M, Hammerer P, Noldus J, Haese A, Pichelmeier U, Erbersdobler A, Henke H, Conrad S, Fernandez S, Huland H. Graefen M, et al. Among authors: haese a. Urologe A. 2000 Jan;39(1):14-21. doi: 10.1007/s001200050004. Urologe A. 2000. PMID: 10663191 Review. German.

8

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.

Haese A, Becker C, Noldus J, Graefen M, Huland E, Huland H, Lilja H. Haese A, et al. J Urol. 2000 May;163(5):1491-7. doi: 10.1016/s0022-5347(05)67649-5. J Urol. 2000. PMID: 10751864

9

Stage migration in clinically localized prostate cancer.

Noldus J, Graefen M, Haese A, Henke RP, Hammerer P, Huland H. Noldus J, et al. Among authors: haese a. Eur Urol. 2000 Jul;38(1):74-8. doi: 10.1159/000020255. Eur Urol. 2000. PMID: 10859445

10

[Therapeutic options in hormone refractory prostate carcinoma].

Graefen M, Hammerer P, Haese A, Huland H. Graefen M, et al. Among authors: haese a. Urologe A. 2000 May;39(3):267-73. doi: 10.1007/s001200050354. Urologe A. 2000. PMID: 10872254 Review. German. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

275 results

Search Page

Filters